Cryo-Cell International, Inc. (CCEL)

Cryo-Cell International's stock price has declined over the past six months, with a share price of $3.52 as of April 29, 2026, a 32.95% decrease from April 30, 2025. The stock traded between $2.72 and $6.35 over the past 52 weeks. In March 2026, the company received a notice from NYSE American regarding non-compliance with listing standards, but in May 2026, NYSE American accepted the company's plan to regain compliance, granting a compliance period through September 9, 2027. The company reported fiscal year 2025 consolidated revenue of $31.6 million and a net loss of $2.4 million.

Information directly detailing the demand seasonality for Cryo-Cell International's products and services is not explicitly available. The company's business model relies heavily on the demand for cord blood and tissue banking services, and a decline in consumer interest could affect revenue.

Cryo-Cell International, Inc. (CCEL) is a biotechnology company specializing in cryopreservation of umbilical cord blood and tissue, founded in 1989 as the world's first private cord blood bank. The company's services include cellular processing and cryogenic storage of umbilical cord blood and cord tissue stem cells for family and public use. They also manufacture PrepaCyte CB processing system units and provide cold storage services to third-party pharmaceutical companies and medical institutions, marketing directly to expectant parents and healthcare professionals.

Cryo-Cell International is headquartered in Oldsmar, Florida, and serves an international market with over 500,000 parents from 87 countries entrusting their cord blood and tissue. Its international presence includes countries in the Americas and Asia. In 2024, Cryo-Cell International opened a new facility in Durham, North Carolina, for cryogenic storage and biotech operations.

Cryo-Cell International has a strong brand reputation as the world's first private cord blood bank and is recognized as an industry leader. The company's facility is FDA registered, cGMP-/cGTP-compliant, and holds accreditations from AABB and FACT. The NYSE American's notice of non-compliance with listing standards in March 2026 could impact its reputation, but the subsequent acceptance of Cryo-Cell's plan to regain compliance by NYSE American in May 2026 demonstrates the company's commitment to addressing these issues and maintaining its listing, which could mitigate potential negative impacts on its reputation. The company also received FACT re-accreditation, further solidifying its quality standards.

Cryo-Cell International has a significant portion of its stock owned by insiders, with 115.45% attributed to them, and 12.20% by institutional shareholders. Major institutional owners include SFI Advisors, LLC, and Vanguard Group Inc. Key individual insider shareholders include Ki Yong Choi, who owns 29.95% of the company's shares.